Matsuda Masaru sold $32K of ARQT

Matsuda Masaru (See Remarks) sold 1,230 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.12 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Matsuda Masaru
Published Aug 6, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosed sale is pre-arranged under Rule 10b5-1, which generally lowers the probability that the transaction reflects new negative information.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 framing makes it more of a routine compliance datapoint than a catalyst.

03

What to watch

The article provides no context on total planned sales, remaining plan size, or whether the sale is part of a larger scheduled program, limiting inference.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Arcutis Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics Form 4 shows officer Matsuda Masaru sold 1,230 shares at $26.1168 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly stated pre-arranged Rule 10b5-1 plan, which typically reduces signaling risk versus discretionary sales.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None.

None.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with management preference for liquidity, which some traders may interpret as caution.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Company whose officer transaction is disclosed on Form 4.

  • Matsuda Masaru

    Officer who sold 1,230 shares.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.